Goldman Sachs analyst David Roman lowered the firm’s price target on Doximity (DOCS) to $50 from $80 and keeps a Neutral rating on the shares after its Q4 results and below-consensus guidance. The company’s top-line growth rate is settling into a narrower range of 10%-11% through FY29 vs. FY25, the analyst tells investors in a research note. Goldman adds that it is forecasting relatively flat adjusted EBITDA margins in FY26 on lower y/y gross margins and investments in R&D.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue